AI-assisted Diagnostic Software for Diabetic Retinopathy (DR)

Indication of Use

VeriSee DR is indicated for use in diabetes clinics and ophthalmology settings to facilitate early detection and referral of diabetic retinopathy, helping to mitigate the risk of vision loss and optimize patient management.

Advantages

AI model trained on images labeled by retina specialists, with a 93% accuracy in referral recommendations.
Supports multiple retinal camera brands and operates independently of a network connection.
Real-time detection of four main DR lesions: Microaneurysms, Hemorrhages, Soft Exudates, and Hard Exudates.
Integrates smoothly with hospital information systems, enhancing workflow and inter-departmental communication.
Validated through a pivotal clinical trial approved by Taiwan FDA, demonstrating high performance metrics including 95% sensitivity and 90% specificity.

Categories Acer Medical, Advanced Diagnostic Technologies, Ophthalmology

Fill in the below to contact us

Description

Downloads